09:19 AM EDT, 07/01/2024 (MT Newswires) -- Vanda Pharmaceuticals ( VNDA ) said Monday that a US District Court in Delaware has allowed its patent lawsuit against Teva Pharmaceuticals USA and Apotex to proceed.

The lawsuit, which was filed in December 2022, alleges that Teva and Apotex infringed Vanda's patent related to its sleep disorder medicine Hetlioz.

Vanda said it plans to request remedies from the court including an order for Teva and Apotex to discontinue marketing their generic versions of Hetlioz.

Teva Pharmaceuticals USA is a unit of Teva Pharmaceutical Industries ( TEVA ) .

Vanda shares were up 2.1% in recent Monday premarket activity.

Price: 5.78, Change: +0.13, Percent Change: +2.30